Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 5/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223236 | 0.78 | CA14 (0.45) | CA14TSHRMEN1KMT2ACA12 | |
| SCHEMBL17130270 | 0.78 | CA14 (0.45) | CA14TSHRMEN1KMT2ACA12 | |
| SCHEMBL23894861 | 0.78 | CA14 (0.45) | CA14TSHRMEN1KMT2ACA12 | |
| SCHEMBL21638018 | 0.78 | CA14 (0.45) | CA14TSHRMEN1KMT2ACA12 | |
| SCHEMBL17130272 | 0.78 | CA14 (0.45) | CA14TSHRMEN1KMT2ACA12 | |
| SCHEMBL14411925 | 0.75 | CA14 (0.42) | CA14TSHRMEN1KMT2ACA12 | |
| SCHEMBL21629443 | 0.72 | TSHR (0.58) | CA14TSHRMEN1KMT2AMAPT | |
| SCHEMBL21368255 | 0.72 | TSHR (0.58) | CA14TSHRMEN1KMT2AMAPT | |
| SCHEMBL8944922 | 0.72 | CA14 (0.43) | CA14TSHRMEN1KMT2ACA12 | |
| SCHEMBL4337217 | 0.70 | SMN1; SMN2 (0.36) | CA14TSHRMEN1KMT2ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088923-B2 | Cyclic-fused beta-lactones and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090062547-A1 | CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS | THE TEXAS A&M UNIVERSITY SYSTEM | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062547-A1 | CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS | COASY, FASN, OTUB1 | CA14 2883/4885TSHR 4563/4885MEN1 3332/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.